Arbutus Biopharma Corporation (ABUS) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Arbutus Biopharma (ABUS) by buying shares or fractional shares at any major US broker, through a biotech ETF that holds it, or as one holding in a thematic basket. Arbutus is a clinical-stage biopharmaceutical company using its virology expertise to develop therapies aimed at a functional cure for chronic hepatitis B (cHBV), led by imdusiran, an RNAi (RNA interference) therapeutic, alongside an oral PD-L1 inhibitor. The single biggest thing to understand is that this is a binary, clinical-stage biotech whose value hinges on trial results and regulatory progress rather than current profits, with an unusual twist: a landmark patent settlement with Moderna over lipid-nanoparticle technology is set to deliver a large cash payment, materially strengthening its balance sheet.
ABUS stock price
As of 2026-07-14, Arbutus Biopharma Corporation (ABUS) last closed at $4.59, up 41.8% over the past year. Over the past 52 weeks it has traded between $3.13 and $5.22.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Arbutus Biopharma Corporation's investor relations page. Walnut is informational, not investment advice.
What does Arbutus Biopharma Corporation (ABUS) do?
Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatitis B virus (cHBV), a disease affecting hundreds of millions of people worldwide for which current treatments rarely cure. Its lead candidate is imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi (RNA interference) therapeutic designed to suppress all HBV antigens, including surface antigen (HBsAg), and it is being studied in combination regimens. Arbutus has reported that a number of patients across its Phase 2a IM-PROVE trials achieved a functional cure when imdusiran was combined with standard antivirals plus agents like pegylated interferon or low-dose immunotherapy, and in 2026 the FDA granted imdusiran Fast Track designation. A second candidate, AB-101, is an oral PD-L1 inhibitor in early clinical testing meant to reawaken the immune response against HBV.
As a clinical-stage biotech, Arbutus has no meaningful product revenue and funds itself through its balance sheet, partnerships, and licensing. The defining recent event is a $2.25 billion global patent settlement with Moderna, reached with its licensee Genevant, resolving litigation over lipid-nanoparticle delivery technology used in COVID-19 vaccines. The structure includes a large noncontingent payment (of which Arbutus expects to receive a sizable share, reported as an estimated $178.7 million, arriving in mid-2026) plus a further contingent amount tied to an appellate ruling. This cash meaningfully extends Arbutus's runway and has prompted the company to evaluate potential shareholder distributions. The investment picture is therefore a blend of clinical-pipeline optionality and an unusually strong, litigation-driven cash position. Verify all trial-status, settlement, and cash figures against Arbutus's latest filings before acting.
What's driving Arbutus Biopharma Corporation (ABUS)?
1. Imdusiran functional-cure program
Imdusiran, an RNAi therapeutic that suppresses HBV antigens, is Arbutus's lead asset and the core of the thesis. The company has reported patients across its Phase 2a IM-PROVE trials achieving a functional cure in combination regimens, with several sustaining it for over two years, and the FDA granted Fast Track designation in 2026. Chronic hepatitis B is a large, underserved market where a true functional cure would be highly valuable, so imdusiran's continued clinical progress is the single biggest driver of long-term value.
2. Moderna settlement and cash
Arbutus and its licensee Genevant reached a $2.25 billion global settlement with Moderna over lipid-nanoparticle patent litigation. The structure includes a large upfront noncontingent payment plus a contingent amount tied to an appellate ruling, with Arbutus expecting to receive a sizable share in mid-2026. This influx dramatically strengthens a small biotech's balance sheet, extending runway to fund trials and even prompting the company to evaluate returning capital to shareholders.
3. Combination and pipeline breadth
Arbutus is pursuing a functional cure through combination therapy, pairing imdusiran with standard antivirals and agents like pegylated interferon or immunotherapeutics, and it has a second candidate, AB-101, an oral PD-L1 inhibitor meant to reawaken HBV-specific immunity. This multi-mechanism approach reflects the scientific consensus that curing chronic HBV likely requires combining several distinct mechanisms, and gives Arbutus more than one shot on goal.
4. Regulatory and partnering optionality
Fast Track designation for imdusiran can facilitate development and potentially speed FDA review, a meaningful signal for a small biotech. With a strengthened balance sheet, Arbutus has flexibility to advance trials independently or pursue partnerships and licensing. How the company deploys its settlement cash, whether toward accelerating the pipeline, business development, or shareholder distributions, is an important part of the forward story alongside the clinical data itself.
What are the risks to Arbutus Biopharma Corporation (ABUS)?
Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. Curing chronic hepatitis B is scientifically hard, and functional-cure results seen in small Phase 2a groups may not hold up in larger, later-stage trials, which would sharply reduce the stock's value. The candidates still face years of development, regulatory uncertainty, and competition from other companies pursuing HBV cures. The Moderna settlement, while transformative, has a large contingent portion tied to an appellate ruling that may not be received in full, and the value of the cash depends on how wisely management deploys it. Biotech stocks are volatile and can move sharply on single data readouts. Investors should treat ABUS as a high-risk, potentially high-reward position rather than a stable holding.
How is Arbutus Biopharma Corporation (ABUS) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arbutus Biopharma Corporation's investor relations page or your broker.
- Stage: Clinical-stage biotech; no meaningful product revenue
- Lead asset: Imdusiran (AB-729), RNAi for chronic hepatitis B, Phase 2a, FDA Fast Track
- Second asset: AB-101, oral PD-L1 inhibitor, early clinical
- Moderna settlement: $2.25B global settlement (noncontingent ~$950M plus ~$1.3B contingent); Arbutus expects ~$178.7M share in mid-2026 (verify live)
- Cash position: Reported around ~$95 million before settlement proceeds (as of an early-2026 quarter; confirm live)
- Profitability: Operating at a loss, typical of clinical-stage biotech; settlement revenue distorts recent reported results
These figures are approximate and tied to the Jul 2026 asOf date; verify live trial status, settlement terms and receipts, and cash figures against Arbutus's latest quarterly filings before acting. Traditional valuation multiples do not apply cleanly to a pre-revenue biotech: the stock is driven by clinical data, regulatory milestones, and, unusually here, the litigation settlement cash, so earnings snapshots are less meaningful than pipeline progress and balance-sheet strength.
Who competes with Arbutus Biopharma Corporation (ABUS)?
Hepatitis B cure developers
Arbutus competes with other companies pursuing a functional cure for chronic hepatitis B, including programs at Gilead Sciences, GSK (with its antisense and other HBV assets), Vir Biotechnology, and Assembly Biosciences. The race is to demonstrate durable functional cure in larger trials, and success by a competitor could diminish imdusiran's commercial opportunity.
RNAi and antiviral platforms
As an RNAi developer, Arbutus operates in the same broad scientific space as RNAi leaders like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, the latter of which also has HBV programs. These companies validate the RNAi approach but also compete for scientific mindshare, partnerships, and, in HBV specifically, the same patient population.
Broader clinical-stage biotech
For investors, ABUS also competes for capital with the wider universe of small- and mid-cap clinical-stage biotechs. Its unusual settlement-driven cash position differentiates it from typical cash-hungry peers, but it shares their fundamental dependence on binary trial outcomes and high volatility.
How to invest in Arbutus Biopharma Corporation (ABUS)
There are three common ways to get ABUS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ABUS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ABUS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Arbutus Biopharma Corporation (ABUS)
Arbutus is a clinical-stage hepatitis B biotech built around its RNAi candidate imdusiran, made unusual by a multi-billion-dollar patent settlement with Moderna that is bolstering its cash. Upside depends on functional-cure trial data and regulatory progress; the downside is the ordinary high risk of an unprofitable, pipeline-dependent biotech.
Build a basket around ABUS with Walnut
Use Arbutus Biopharma Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ABUS a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is promising imdusiran functional-cure data, FDA Fast Track designation, and an unusually strong cash position from the Moderna settlement. The bear case is the ordinary high risk of an unprofitable clinical-stage biotech whose value hinges on trial results that can fail, plus uncertainty over the contingent settlement portion. Treat it as high-risk and verify current figures first.
What does Arbutus Biopharma actually do?
+
Arbutus is a clinical-stage biotech developing therapies aimed at a functional cure for chronic hepatitis B. Its lead candidate, imdusiran, is an RNAi (RNA interference) drug that suppresses hepatitis B antigens, studied in combination with other agents. A second candidate, AB-101, is an oral PD-L1 inhibitor meant to reawaken the immune response against the virus. It has no approved products generating meaningful revenue yet.
What is the Moderna settlement about?
+
Arbutus and its licensee Genevant reached a $2.25 billion global settlement with Moderna resolving patent litigation over lipid-nanoparticle delivery technology used in COVID-19 vaccines. The structure includes a large upfront noncontingent payment plus a further amount contingent on an appellate ruling. Arbutus expects to receive a sizable share (reported around $178.7 million) in mid-2026, which materially strengthens its balance sheet.
Is imdusiran close to approval?
+
Not yet. Imdusiran is in Phase 2a trials, an early clinical stage, though it has shown functional cure in a number of patients in combination regimens and received FDA Fast Track designation in 2026, which can help speed development and review. It still faces larger, later-stage trials and regulatory review that take years, and results in small early trials may not hold up at scale.
Does Arbutus pay a dividend?
+
Arbutus has been a pre-revenue, loss-making biotech that does not pay a regular dividend. However, after the large Moderna settlement, the company has said it is evaluating potential shareholder distributions. Any such move would be unusual for a clinical-stage biotech and is not guaranteed, so check the company's latest announcements before assuming any capital return.
Why is ABUS considered high risk?
+
Arbutus is an unprofitable clinical-stage biotech whose value depends on trial outcomes that can fail at any stage. Curing chronic hepatitis B is scientifically difficult, early functional-cure results may not hold in larger trials, and the stock can swing sharply on single data readouts. Even the settlement has a contingent portion that may not arrive in full. These are speculative, binary dynamics rather than stable fundamentals.
How can I get exposure to Arbutus through an ETF?
+
ABUS appears in various biotechnology and small-cap ETFs, where it sits among many clinical-stage drug developers. ETF exposure spreads the high single-stock risk of any one biotech across dozens of holdings, which can be sensible given how binary individual biotech outcomes are. Always check a fund's holdings and weighting before assuming meaningful exposure to Arbutus specifically.
What are the main risks of investing in ABUS?
+
The central risk is clinical failure: as a pre-revenue biotech, Arbutus depends on trial results that may not succeed, and functional-cure data from small early trials may not replicate at scale. It also faces regulatory uncertainty, competition from other HBV-cure programs, and dependence on how well management deploys the settlement cash. The contingent portion of the Moderna settlement is not assured, and biotech shares are highly volatile.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Arbutus Biopharma Corporation's investor relations page or your broker before making investment decisions.